Inclusion Criteria:

• Have BPH LUTS based on the disease diagnostic criteria at 1st screening.
• Have a history of ED based on the disease diagnostic criteria at 1st screening.
• Have Lower Urinary Tract Symptoms (LUTS) with a Total IPSS greater than or equal to 13 at 2nd screening.
• Have bladder outlet obstruction as defined by a Qmax of greater than or equal to 4 to less than or equal to 15 mL/second (from a prevoid total bladder volume as assessed by ultrasound of greater than or equal to 150 to less than or equal to 550 mL and a minimum voided volume of 125 mL) at 2nd screening.
• Make at least 4 sexual intercourse attempts during the 4-weeks after 2nd screening as recorded in the SEP diary.
• Are sexually active with an adult female partner, and expect to remain sexually active with the same adult female partner for the duration of the study.
• Agree not to use any other approved or experimental BPH, OAB, or ED treatments as indicated in the protocol at any time during the study.
• Have not taken treatments indicated in the protocol prior to the 2nd screening.

Exclusion Criteria:

• Current treatment with nitrates.
• PSA greater than 10.0 ng/mL at 1st screening.
• PSA greater than or equal to 4.0 to less than or equal to 10.0 ng/mL at 1st screening if prostate malignancy has not been ruled out to the satisfaction of a urologist.
• Clinical evidence of prostate cancer.
• Bladder PVR greater than or equal to 300 mL by ultrasound determination at 1st screening.
• History or clinical evidence of certain pelvic, bladder, urinary tract, or urinary retention conditions described in the protocol.
• Lower urinary tract instrumentation (including prostate biopsy) within 30 days of 1st screening.
• Clinical evidence of severe hepatic impairment at 1st screening.
• Current neurologic disease or condition associated with neurogenic bladder (for example, Parkinson's disease or multiple sclerosis).
• History of significant renal insufficiency as defined by the protocol.
• History of ED caused by other primary sexual disorders including premature ejaculation or ED caused by untreated endocrine disease.
• Presence of penile deformity judged by the investigator to be clinically significant.
• History of certain cardiac or cardiovascular conditions described in the protocol.
• History of resuscitated cardiac arrest.
• Current treatment with certain medications described in the protocol.
• Scheduled or planned surgery (or any procedure requiring general, spinal, or epidural anesthesia) during the course of the study.
• History of significant central nervous system injuries (including stroke or spinal cord injury) within 6 months of 1st screening.
• HbA1c greater than 9% at 1st screening.
• Prior treatment with PDE5 inhibitors judged by the investigator to be ineffective. However, if the investigator judges that a subject's lack of response to as-needed PDE5 inhibitors is the result of inadequate coordination between dosing and sexual activity with a treatment, the subject may be enrolled.